News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BIND Therapeutics Reports Third Quarter 2013 Financial Results



11/5/2013 7:11:01 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

BIND Therapeutics, Inc. (NASDAQ: BIND) a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results for the three-month period ended September 30, 2013.

“In the third quarter, BIND made significant progress, including the initiation of two Phase 2 studies of our proprietary lead Accurin, BIND-014, in non-small cell lung cancer and metastatic castrate-resistant prostate cancer,” said Scott Minick, BIND’s President and CEO.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES